Apple’s lawsuit accusing OpenAI of obtaining trade secrets through former employees raises questions about corporate ethics, recruitment practices, confidentiality agreements, and OpenAI’s hardware ambitions. The panel considers the potential legal and financial consequences before examining Apple’s plan to end support for encrypted HFS+ volumes and what users should do with older drives.Panel members include: Chuck Joiner, David Ginsburg, Marty Jencius, Eric Bolden, Brian Flanigan-Arthurs, Jim Rea, Web Bixby, Jeff Gamet, and Mark Fuccio.

💾

The MacVoices Live! panel dives deep into Apple’s across-the-board price increases, weighing rising RAM, storage, inflation, shareholder obligations, and product value. Chuck Joiner, David Ginsburg, Brian Flanigan-Arthurs, Ben Roethig, Eric Bolden, Marty Jencius, Jeff Gamet, Norbert Frassa, Jim Rea, and Web Bixby debate whether higher prices are a short-term reset or the new normal, how buyers may react, why the MacBook Neo increase stings, and whether refurbished or education pricing may become more important. 

💾

AI is taking on a growing role in cybersecurity (whether we like it or not), from vulnerability discovery to faster exploit development. Chuck Joiner, David Ginsburg, Eric Bolden, Web Bixby, Jim Rea, Brian Flanigan-Arthurs, Jeff Gamet, and Marty Jencius look at both sides oof the issue and  push back on “Bugmageddon” hype. The discussion also covers X post limits, Microsoft Teams retiring the misguided Together Mode, safer login practices, AI-run radio chaos, Google’s Apple-like naming choices, and free storage tied to phone numbers. 

💾

At NAB 2026, Larry O’Connor of Other World Computing discusses the new Express 4M2 Ultra, a Thunderbolt 5-certified, four-blade M.2 DIY storage solution built for speed, quiet operation, and thermal control. The conversation also covers OWC’s dual 10G dock, StudioStack, Helios 5S PCIe chassis, and the company’s focus on reliable, accessible technology for creators, prosumers, […]

💾

Un désastre exceptionnel s'est produit dans l'une des plus grandes villes du Canada il y a quelques années. Un orage de grêle géante a tout pulvérisé sur son passage, à tel point que le coût des dégâts a atteint un niveau impensable.

Un froid polaire, des vents dignes de ceux d’un ouragan, un isolement total en hiver… Bienvenue au Groenland ! Comment vit-on sur l'île la plus extrême du monde au niveau climatique ? Découvrez le quatrième épisode de ma série de cinq reportages inédits Un été au Groenland.

Le Groenland suscite les convoitises, les tensions, mais aussi, l’admiration. À première vue, cette île glacée du pôle nord semble sans aucun intérêt et pourtant tout le monde veut s’en emparer : les grands dirigeants de la Planète, les scientifiques et, plus récemment, les touristes du monde...

99 % des infarctus et des AVC survenus dans une cohorte de plus de neuf millions d'adultes ont été précédés d'au moins un facteur de risque parmi quatre. L'idée d'un accident cardiaque qui frappe sans prévenir en sort ébranlée. Une autre étude nuance toutefois le tableau, en particulier chez les...

Pour Marcio Cabral et sa photo Pandora, ce n’est pas qu’une récompense de plus que celle décernée à l’occasion de la COP17 Désertification qui se tient en Mongolie jusqu’au 28 août. C’est la victoire de l’émerveillement sur la résignation. Certes l’image ne suffit pas à tout réparer à elle...

Petlibro founder and CEO York Wu provided more information about an outage that left users unable to control their smart pet feeders through the companion app and, in some reported cases, left them with hungry pets.

Petlibro, a company owned by Shenzhen, China-headquartered firm Shenzhen Libro Technology Co., first acknowledged the outage on Tuesday at 5 am PT. At 7 pm PT on Wednesday, Petlibro said the outage was resolved. Notably, some people online reported different information at the time, and some claimed to still have problems as of August 13.

In a blog post on Saturday that included an apology and acknowledgement of the “frustration and concern” the outage caused, Wu confirmed that problems with Petlibro’s cloud server caused the outage:

Read full article

Comments

© Petlibro

The Marcus Foundation has awarded $28.7 million to Chuck Murry, MD, PhD, director of the USC Stem Cell Center, to support a clinical trial testing a stem cell-based therapy intended to regenerate heart muscle damaged by a severe heart attack. The award, the largest the foundation has given to the University of Southern California and one of its largest contributions to academic medicine, will fund both the planned human study and a parallel research program examining how the immune system responds to transplanted cardiac cells.

The trial is scheduled to begin in 2027 at Keck Hospital of USC in partnership with the USC Cardiac and Vascular Institute. A second clinical site will be established at the University of Washington, where elements of the technology were originally developed. The first phase will enroll approximately 18 patients who have experienced extensive myocardial infarction, the medical term for a heart attack that destroys part of the heart’s muscular wall.

Patients in the study will receive stem-cell-derived heart muscle cells delivered into regions damaged by the infarction. The primary goals will be to evaluate safety and determine whether the procedure is feasible in people with severe cardiac injury. Investigators will also monitor early biological signals, including whether the transplanted cells remain active, integrate with the injured tissue and produce measurable changes in cardiac performance during recovery and long-term follow-up.

A heart attack occurs when blood flow through a coronary artery is blocked, depriving cardiac muscle of oxygen. Within minutes, cells in the affected region begin to die, and the resulting scar tissue lacks the contractile properties of healthy myocardium. Unlike tissues such as skin or blood, adult human heart muscle has only a limited capacity for self-repair. As a result, a large infarction can weaken the heart’s pumping function, increase the risk of heart failure and leave survivors unable to perform ordinary activities without fatigue or breathlessness.

Current cardiovascular treatments can reopen blocked arteries, limit further injury and help the remaining heart muscle work more efficiently. They cannot, however, routinely replace the cardiomyocytes that have already been lost. Murry’s research program is aimed at addressing that biological gap by producing replacement heart muscle cells in the laboratory and delivering them directly to damaged tissue. The strategy represents a shift from supporting a failing heart to attempting to rebuild part of its contractile apparatus.

The transplanted cells are being developed as a form of cellular therapy, in which living cells act as the therapeutic agent rather than serving merely as a vehicle for a drug. According to Murry, the cells are intended to become active within the injured heart, contribute to repair and synchronize with surrounding muscle. Achieving that outcome requires more than placing new cells into scarred tissue: the cells must survive, connect functionally with the host myocardium and avoid creating dangerous electrical disturbances or abnormal rhythms. The initial trial is therefore designed principally to establish safety before testing therapeutic effectiveness in larger patient groups.

The foundation’s funding will also support research into the immune response triggered by cell transplantation. Even cells created from stem cells can be recognized as foreign by the recipient’s immune system, potentially leading to inflammation or destruction of the transplanted population. Patients who receive cellular grafts may consequently require immunosuppressive drugs, which can increase susceptibility to infection and produce other long-term complications. Researchers will study how immune cells interact with the implanted cardiac cells and investigate methods that could reduce or eventually eliminate the need for chronic immunosuppression.

The work builds on approximately three decades of research by Murry and his collaborators to move regenerative cardiology from laboratory experiments toward clinical treatment. The program includes gene-edited cellular technology, intended to improve the compatibility or performance of therapeutic cells in the human body. The precise effectiveness of the approach will not be known until it is tested in patients, and the small 2027 cohort will not be large enough to determine whether the therapy improves survival or prevents heart failure. Those questions would require subsequent trials involving substantially more participants and longer observation.

The Marcus Foundation described the project as a potential turning point for regenerative medicine, while USC leaders said the investment could create a platform for developing additional cellular therapies. The immediate scientific challenge is to determine whether transplanted heart muscle cells can be delivered safely and function meaningfully within severely damaged human hearts. If the trial meets its safety and feasibility objectives, it could provide the clinical evidence needed to advance a new generation of treatments for myocardial infarction—therapies designed not only to help patients live with damaged cardiac tissue, but to restore some of the function that conventional medicine cannot yet replace.

Subject of Research: Stem cell-based regenerative therapy for heart muscle damaged by myocardial infarction

Article Title: $28.7 Million Award Supports USC Trial of Stem Cell Therapy to Regenerate Heart Muscle After Heart Attack

Web References: The Marcus Foundation: https://marcusfoundation.org/; USC Stem Cell Center: https://stemcell.keck.usc.edu/; Chuck Murry Lab: https://murrylab.usc.edu/charles-chuck-murry-md-phd/; USC Cardiac and Vascular Institute: https://www.keckmedicine.org/services/cardiovascular/; Keck School of Medicine of USC: https://keck.usc.edu/

Image Credits: Steve Cohn

Keywords: Heart disease, myocardial infarction, heart attack, heart muscle, stem cell research, stem cell therapy, cell therapy, regenerative medicine, cardiovascular disorders, heart failure, clinical trial, cardiac regeneration

A climate shock that unfolded about 304 million years ago is offering scientists a dramatic warning about how quickly Earth’s climate system can amplify an initial temperature rise. During the Late Paleozoic Ice Age, a relatively modest increase in global temperatures appears to have triggered a much larger episode of warming, as methane released from thawing permafrost intensified the greenhouse effect. Researchers say the ancient event provides a powerful geological parallel for the climate changes occurring today.

The study, led by Le Yao of the Nanjing Institute of Geology and Paleontology with contributions from University of Cincinnati geosciences professor Thomas Algeo and international colleagues, examined a short-lived warming episode during Earth’s penultimate ice age. Their findings suggest that global sea surface temperatures eventually increased by more than 7 degrees Celsius, or approximately 12 degrees Fahrenheit. The rise was not necessarily caused by one enormous initial pulse of carbon. Instead, it may have developed through a chain reaction in which warming activated additional natural sources of greenhouse gases.

The Late Paleozoic Ice Age extended across a vast span of geological time, when large ice sheets covered parts of the supercontinent Gondwana. Although the planet was in an “icehouse” state, atmospheric carbon dioxide and methane still had the power to destabilize the climate. The newly analyzed warming event is particularly significant because it occurred under ice-age conditions rather than during an already warm greenhouse world. That makes it a valuable analog for the modern Earth, which still contains continent-scale ice masses in Greenland and Antarctica.

According to the researchers, the initial climate disturbance may have been linked to volcanic activity. Volcanic emissions can inject carbon dioxide and other gases into the atmosphere, where they absorb outgoing infrared radiation and prevent some heat from escaping into space. The warming may also have been assisted by changes in Earth’s orbit. Over long cycles, variations in orbital shape alter the distribution of sunlight across the planet, influencing the growth and retreat of ice sheets and changing the seasonal balance of solar energy.

At first, the additional carbon may have produced only a limited temperature increase. But once warming crossed a critical threshold, frozen ground in high-latitude regions began to thaw. Permafrost contains large quantities of organic carbon preserved in frozen soils. When that material becomes available to microbes, decomposition can release carbon dioxide and methane. Methane is especially powerful over shorter atmospheric timescales because, molecule for molecule, it absorbs considerably more infrared radiation than carbon dioxide, even though it remains in the atmosphere for less time.

This process can create a positive climate feedback. An initial warming causes permafrost to thaw, thawing releases greenhouse gases, and the additional gases produce further warming. That extra heat can accelerate more thawing, allowing the cycle to reinforce itself. The researchers describe the ancient event as a transient global warming episode in which a comparatively modest carbon release appears to have crossed a climatic tipping point and initiated much more extensive carbon emissions from natural reservoirs.

The geological timescale of the ancient warming is also central to the study’s relevance. Algeo said the temperature change unfolded over tens of thousands of years, with warming occurring at an average rate of roughly one-tenth of a degree Celsius per 1,000 years. Modern warming is progressing far more rapidly. Researchers have observed an increase of nearly 1 degree Celsius in global sea surface temperature over approximately the past century, a rate many times faster than the average change reconstructed for the ancient event.

The comparison does not mean that Earth is destined to repeat the precise conditions of 304 million years ago. Continents, ecosystems, atmospheric composition and ice-sheet geometry were all different in the Late Paleozoic. However, the physics of greenhouse warming and the existence of carbon feedbacks remain relevant. Ancient climate records reveal how a system that appears stable can respond nonlinearly when warming activates processes capable of releasing additional greenhouse gases.

The findings also place human history in a broader planetary context. All recorded human civilization has developed during the most recent ice age, despite the fact that the term can sound incompatible with today’s climate. In scientific usage, Earth remains in an ice age because substantial permanent ice sheets still exist in Greenland and Antarctica. The ancient warming episode matters precisely because it demonstrates that an ice age does not guarantee a permanently cold or stable climate. Even within an icehouse world, a small disturbance can trigger rapid and substantial changes when reinforcing feedbacks are engaged.

The research, published in the Proceedings of the National Academy of Sciences, underscores why scientists closely monitor permafrost, polar ice and other climate-sensitive carbon stores. The ancient record cannot provide an exact forecast of future warming, but it shows that Earth’s climate has repeatedly responded to carbon disturbances with amplifying feedbacks. As modern emissions continue to raise temperatures at an exceptional rate, the geological evidence offers a clear message: the danger lies not only in the carbon released directly by human activity, but also in the natural carbon sources that warming can unlock.

Subject of Research: Ancient global warming, permafrost methane feedbacks, and climate tipping points during the Late Paleozoic Ice Age

Article Title: A transient global warming event during Earth’s penultimate icehouse

Web References: https://doi.org/10.1073/pnas.2601643123

References: Proceedings of the National Academy of Sciences, DOI: 10.1073/pnas.2601643123

Image Credits: Andrew Higley, University of Cincinnati

Keywords: climate change, global warming, ice age, Late Paleozoic Ice Age, permafrost, methane, climate feedback, tipping point, paleoclimate, geology, volcanic activity, Earth’s climate history

A research team in Japan has won a US$1 million Milestone 2 award in the XPRIZE Healthspan competition for developing engineered “super exosomes,” microscopic biological delivery vehicles designed to target aging and damaged cells. Led by Professor Keisuke Goda of Tohoku University’s SiRIUS Institute of Medical Research and Graduate School of Medicine, in collaboration with researchers from the University of Tokyo’s Department of Chemistry, the team was selected from more than 600 competitors worldwide.

XPRIZE Healthspan is a seven-year international competition focused on extending the period of life people spend in good health. Participating teams are challenged to develop treatments capable of restoring muscle, cognitive, and immune function in adults between 50 and 90 years old. The competition sets a minimum target of reversing at least 10 years of biological decline, while the most ambitious goal is a 20-year improvement within one year or less of treatment. Goda’s team is now moving forward after receiving recognition for results obtained in aged animal studies.

At the center of the research are exosomes, naturally occurring nanoparticles released by cells. These membrane-bound vesicles normally transport proteins, lipids, messenger RNA, and other molecular signals between cells, functioning as part of the body’s communication network. Because exosomes can carry biological cargo and interact with specific tissues, scientists have been investigating them as potential alternatives to synthetic drug-delivery systems. However, naturally produced exosomes often lack sufficient targeting precision, limiting their ability to reach the cells most relevant to a disease or aging process.

The Tohoku-led group attempted to solve that problem by chemically modifying the surface of exosomes with lanthanide ions. Lanthanides are a family of metallic elements with distinctive electronic and chemical properties. According to the researchers, attaching these ions changes the surface behavior of the exosomes and substantially improves their ability to recognize and bind to senescent cells. The resulting particles have been named “super exosomes,” a term that reflects their enhanced targeting and delivery capabilities rather than a new biological category.

Cellular senescence is one of the major biological processes associated with aging. Senescent cells have generally stopped dividing because of accumulated damage or stress, but they do not necessarily disappear. Instead, some remain metabolically active and release inflammatory molecules, growth regulators, and other signals that can disrupt nearby tissues. This collection of secreted factors, often called the senescence-associated secretory phenotype, can contribute to chronic inflammation, impaired tissue repair, and the deterioration of organs. Precisely influencing these cells has therefore become a major objective in longevity research.

The proposed super-exosome platform is designed to deliver regenerative molecular cargo directly to aging tissues after attaching to senescent cells. Potential cargoes include growth factors, messenger RNA, and other genetic materials capable of altering cellular behavior. Rather than distributing such molecules broadly throughout the body, a targeted exosome could concentrate them near damaged or dysfunctional tissue. In theory, this approach could promote repair while reducing unwanted effects in healthy cells, although the degree of targeting and the durability of the response will need to be confirmed in human studies.

In preclinical experiments involving several groups of aged mice, the researchers reported statistically significant improvements in frailty, physical performance, and multiple functional measures associated with aging. They also described the treatment’s safety profile as excellent in the studies conducted so far. The team says the overall benefit corresponds to more than 15 additional healthy human years when estimated using cross-species lifespan scaling. Such calculations can help compare biological effects between species, but they are not evidence that a mouse treatment will extend human life by a specific number of years. Human biology, dosing, immune responses, and long-term risks could differ substantially.

The award will support the next stage of development: clinical studies planned in collaboration with Tohoku University Hospital and the Tohoku University Healthspan Research Center. These studies will need to establish how the particles behave in humans, how efficiently they reach senescent cells, what cargoes are most effective, and whether the treatment produces measurable improvements in strength, cognition, immunity, or other healthspan indicators. Researchers will also have to monitor possible immune reactions, unintended effects on healthy tissues, changes in tumor risk, and the persistence of engineered exosomes in the body. These questions are essential before claims of age reversal can move beyond the laboratory.

The platform could eventually be investigated for conditions involving muscle decline, cognitive impairment, immune dysfunction, hair loss, skin aging, and reproductive health. The team plans to commercialize the technology through NanoTitan, with the aim of developing scalable manufacturing and international distribution for exosome-based therapeutics produced in Japan. “Advancing to the XPRIZE Healthspan finals is an important milestone, but our ultimate goal is to translate this technology into therapies that allow people to lead healthy, independent, and active lives longer,” Goda said. The research now enters its most demanding phase: determining whether an impressive result in aged mice can become a safe, reproducible, and clinically meaningful treatment for people.

Subject of Research: Engineered “super exosomes” designed to target senescent cells and deliver regenerative molecular cargo for healthy aging.

Article Title: Japanese Research Team Wins US$1 Million XPRIZE Award for “Super Exosome” Aging Technology

Web References: https://mediasvc.eurekalert.org/Api/v1/Multimedia/673c8fb3-268a-4a90-93b4-a0d531624a52/Rendition/low-res/Content/Public

Image Credits: Goda Lab

Keywords: Super exosomes, exosomes, cellular senescence, healthy aging, longevity research, XPRIZE Healthspan, regenerative medicine, Tohoku University, lanthanide ions, aged mice, healthspan, nanomedicine

The price of saving a newborn’s life can extend far beyond the hospital walls. A new analysis published in the Journal of Perinatology is drawing attention to a largely invisible consequence of neonatal intensive care: the direct medical out-of-pocket costs paid by families. The study, led by researchers Gorka, Profit and Phibbs, examines who carries the greatest financial burden during a neonatal intensive care unit admission and investigates how structural conditions may shape those costs.

Neonatal intensive care is among the most technologically advanced forms of medicine. Infants in NICUs may require mechanical ventilation, incubators that regulate temperature and humidity, continuous heart and oxygen monitoring, intravenous nutrition, specialized medications and repeated laboratory testing. These interventions can be lifesaving, particularly for babies born extremely prematurely or with serious medical complications. Yet the financial consequences of receiving this care are not experienced equally by every household, even when families receive treatment in the same health-care system.

The researchers’ focus is direct medical out-of-pocket spending: the money families must pay themselves for medical services connected to a NICU admission. This can include deductibles, copayments, coinsurance and other forms of cost sharing that remain after insurance has paid its portion. Unlike the total hospital charge or the amount reimbursed by an insurer, out-of-pocket cost reflects the portion that reaches a family’s own budget. For households already coping with an unexpected high-risk birth, even relatively small individual charges can accumulate rapidly.

The study is designed not only to document these expenses, but also to explore the structural forces behind differences in cost burden. In health economics, structural contributions refer to the way institutions and systems distribute risk and resources. Insurance design, employment-linked coverage, household income, geographic location, hospital characteristics and access to public assistance can all affect how much a family ultimately pays. Two infants with similar clinical needs may therefore generate very different financial experiences for their parents, depending on the architecture of coverage surrounding them.

That distinction matters because the effects of a NICU admission are not limited to the newborn’s medical condition. Parents may need to travel long distances to reach a specialized hospital, arrange accommodation near the facility, pay for transportation or meals, and take unpaid leave from work. These expenses may not always appear in estimates of direct medical out-of-pocket costs, but they can intensify the economic shock associated with a prolonged admission. The medical bill is only one component of the broader financial strain that can accompany neonatal illness.

A central question raised by the analysis is whether the families with the fewest financial resources are also the ones most exposed to high cost sharing. A payment that is manageable for a high-income household may consume a substantial share of a lower-income family’s monthly budget. Economists often describe this pattern as a disproportionate cost burden: the absolute amount paid may not be the highest, yet the payment represents a greater fraction of household resources. This distinction can reveal inequities that remain hidden when researchers look only at average dollar amounts.

The findings are expected to be relevant to health-policy debates about medical debt, insurance protection and the financial consequences of premature birth. If structural factors account for meaningful differences in family payments, reducing inequality may require more than improving clinical care. Potential responses could include limits on neonatal cost sharing, stronger protections against unexpected bills, expanded eligibility for public coverage and assistance with transportation or family support services. The analysis may also help hospitals and policymakers identify families at risk of financial hardship while an infant is still receiving care.

The issue has significance beyond individual hospitalizations because NICU care can influence a family’s financial stability long after discharge. Parents may face follow-up appointments, medications, developmental assessments and specialist care for children who experienced complications of prematurity or serious illness. Medical expenses can overlap with reduced work hours, job loss or the need for one parent to become a full-time caregiver. A short period of intensive treatment can therefore produce a long economic aftershock, particularly when families lack savings or paid leave.

By placing family payments at the center of neonatal research, Gorka, Profit and Phibbs emphasize a dimension of NICU care that is often absent from clinical success measures. Survival, complications and length of stay remain essential indicators, but they do not fully describe the experience of families navigating intensive care. Understanding who pays the most, why they pay it and how those payments relate to broader social structures could help redefine quality in neonatal medicine. The study’s message is potentially viral because it connects cutting-edge life-saving technology with a simple but consequential question: when medicine saves a baby, how much of the cost is left for the family to survive?

Subject of Research: Direct medical out-of-pocket costs of neonatal intensive care admissions and structural factors contributing to differences in financial burden among NICU families.

Article Title: Who pays the most for neonatal intensive care? An analysis of the out-of-pocket cost burden borne by NICU families

Article References: Gorka, N., Profit, J. & Phibbs, C.S. “Who pays the most for neonatal intensive care? An analysis of the out-of-pocket cost burden borne by NICU families.” Journal of Perinatology (2026). https://doi.org/10.1038/s41372-026-02869-6

Image Credits: AI Generated

DOI: 10.1038/s41372-026-02869-6

Keywords: neonatal intensive care, NICU, out-of-pocket costs, medical expenses, health-care inequality, premature birth, financial burden, insurance, neonatal health, health policy

La lumière glisse sur la Méditerranée comme une caresse dorée, semant mille éclats à la surface de l’eau. Lovée entre les reliefs du littoral varois, la baie des Lecques déroule son rivage face à un horizon où le bleu du ciel se confond avec celui de la mer. À Saint-Cyr-sur-Mer, pins, roches et...

Labour has edged ahead of Reform for the first time in 18 months as more of its 2024 voters return to the fold, with Reform meanwhile leaking support to the Conservatives.

The post Labour Overtakes Reform in Polls for First Time in 18 Months as 2024 Voters Return appeared first on The Daily Sceptic.

BlueFerry traz iMessage e SMS do iPhone direto para Linux via Bluetooth, sem depender de Mac ou nuvem.

O post BlueFerry: iMessage e SMS do iPhone chegam ao Linux por Bluetooth apareceu primeiro em Blog do Edivaldo - Informações e Notícias sobre Linux.

Dans les profondeurs océaniques, produire sa propre lumière peut sembler risqué. Pourtant, la bioluminescence constitue un précieux outil de survie pour de nombreuses espèces. Chez le plus grand vertébré lumineux connu, elle pourrait même remplir une fonction inattendue.